Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,850 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Preliminary report on harmonization of features extraction process using the ComBat tool in the multi-center "Blue Sky Radiomics" study on stage III unresectable NSCLC.
Cabini RF, Brero F, Lancia A, Stelitano C, Oneta O, Ballante E, Puppo E, Mariani M, Alì E, Bartolomeo V, Montesano M, Merizzoli E, Aluia D, Agustoni F, Stella GM, Sun R, Bianchini L, Deutsch E, Figini S, Bortolotto C, Preda L, Lascialfari A, Filippi AR. Cabini RF, et al. Among authors: sun r. Insights Imaging. 2022 Mar 7;13(1):38. doi: 10.1186/s13244-022-01171-1. Insights Imaging. 2022. PMID: 35254525 Free PMC article.
A score combining baseline neutrophilia and primary tumor SUVpeak measured from FDG PET is associated with outcome in locally advanced cervical cancer.
Schernberg A, Reuze S, Orlhac F, Buvat I, Dercle L, Sun R, Limkin E, Escande A, Haie-Meder C, Deutsch E, Chargari C, Robert C. Schernberg A, et al. Among authors: sun r. Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):187-195. doi: 10.1007/s00259-017-3824-z. Epub 2017 Sep 15. Eur J Nucl Med Mol Imaging. 2018. PMID: 28916879
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R, Limkin EJ, Vakalopoulou M, Dercle L, Champiat S, Han SR, Verlingue L, Brandao D, Lancia A, Ammari S, Hollebecque A, Scoazec JY, Marabelle A, Massard C, Soria JC, Robert C, Paragios N, Deutsch E, Ferté C. Sun R, et al. Lancet Oncol. 2018 Sep;19(9):1180-1191. doi: 10.1016/S1470-2045(18)30413-3. Epub 2018 Aug 14. Lancet Oncol. 2018. PMID: 30120041
Role of image-guided biopsy and radiomics in the age of precision medicine.
Tselikas L, Sun R, Ammari S, Dercle L, Yevich S, Hollebecque A, Ngo-Camus M, Nicotra C, Deutsch E, Deschamps F, de Baere T. Tselikas L, et al. Among authors: sun r. Chin Clin Oncol. 2019 Dec;8(6):57. doi: 10.21037/cco.2019.12.02. Chin Clin Oncol. 2019. PMID: 31968981 Free article. Review.
Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma.
Boutros C, Chaput-Gras N, Lanoy E, Larive A, Mateus C, Routier E, Sun R, Tao YG, Massard C, Bahleda R, Schwob D, Ibrahim N, Khoury Abboud RM, Caramella C, Lancia A, Cassard L, Roy S, Soria JC, Robert C, Deutsch E. Boutros C, et al. Among authors: sun r. J Immunother Cancer. 2020 Aug;8(2):e000627. doi: 10.1136/jitc-2020-000627. J Immunother Cancer. 2020. PMID: 32819972 Free PMC article. Clinical Trial.
Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells.
Sun R, Sundahl N, Hecht M, Putz F, Lancia A, Rouyar A, Milic M, Carré A, Battistella E, Alvarez Andres E, Niyoteka S, Romano E, Louvel G, Durand-Labrunie J, Bockel S, Bahleda R, Robert C, Boutros C, Vakalopoulou M, Paragios N, Frey B, Soria JC, Massard C, Ferté C, Fietkau R, Ost P, Gaipl U, Deutsch E. Sun R, et al. J Immunother Cancer. 2020 Nov;8(2):e001429. doi: 10.1136/jitc-2020-001429. J Immunother Cancer. 2020. PMID: 33188037 Free PMC article.
7,850 results